Research on discovering and developing new drugs. Covers structure-revealing tools, eye-disease mechanisms, protein screening, and once-daily oral medicines.
Researchers at Lund University have discovered that people with Alzheimer's disease can be identified before symptoms appear, using PET scans to visualize tau and amyloid proteins in the brain. Participants found to have these biomarkers were at a 20-40 times higher risk of developing cognitive decline in the next few years.
Researchers found that MK256 induced differentiation and maturation in leukemia stem cells, inhibiting proliferation of AML cell lines. The study also showed dose-dependent inhibition of the STAT pathway in both in vitro and in vivo studies.
The study reveals the structure of the 15-subunit IFT-B complex, a crucial component in cilia formation and maintenance. The complex's elongated and flexible nature is consistent with previous low-resolution reconstructions, and two configurations are identified that may drive bi-directional movement.
Researchers at OHSU discovered adenosine effectively acts as a brake to dopamine, promoting balance in neuronal signaling. This finding suggests new avenues for drug development to treat Parkinson's disease symptoms by targeting the push-pull dynamic between dopamine and adenosine.
Researchers have developed a transport nanoparticle to deliver an anti-inflammatory drug, Necrosulfonamide (NSA), directly into macrophages to combat inflammatory overactivation. The mesoporous silica nanoparticle is fully biodegradable and non-toxic, showing remarkable efficacy in reducing inflammation.
Regular use of cholesterol-lowering and diabetes-control drugs may lessen the risk of age-related macular degeneration (AMD) in European populations. The pooled data analysis involved 38,694 participants and showed a 15% lower prevalence of any type of AMD with these medications.
Letrozole, a breast cancer treatment drug, shows promise in suppressing liver fibrosis through inhibition of the CTGF pathway and reduction of Hsd17b13 expression. This repurposed approach may lead to new treatments for liver disease.
Researchers from UCLA have developed a strategy to identify novel treatments for cognitive decline and neurodegenerative diseases by exploiting sex differences in the brain. The study provides a roadmap for disentangling the contribution of sex-specific factors, which can yield treatments optimized for each sex.
Researchers found that rapamycin treatment during developmental growth phase decelerates aging rate and extends lifespan in animals. A transient late-life treatment is not effective, but a transient early-life treatment can reprogram aging.
Researchers identified specific monkeypox mutations that contribute to its continued infectiousness. The virus is accumulating mutations where drugs and antibodies from vaccines are supposed to bind, making it smarter and more infectious.
A recent study found worsening disparities in cancer drug trial participant diversity from 2000 to 2018, highlighting systemic biases and unequal access to new treatments. The findings underscore the need for increased diversity in phase 1 clinical trials to ensure equitable access to life-saving treatments.
A study by CeMM researchers and the University of Dundee identifies mutations in E3 ligases that mediate resistances in cell cultures, but also finds that these mutations can be targeted by chemically modified degraders. This understanding has clinical relevance and enables further improvement of cancer therapy drugs.
A new study found that only 12% of middle-aged adults are willing to participate in dementia prevention drug trials, citing concerns over the risks involved. The study suggests prioritizing those with a family history or perceived personal risk for dementia and communicating about trial safety could increase participation.
Researchers mapped the detailed neural pathway of defensive responses from the gut to the brain in mice after detecting germs. The study could lead to better anti-nausea medications for cancer patients undergoing chemotherapy.
The research reveals PAPP-A's heart-shaped structure and its interaction with STC2, a key regulator of IGF conversion. The study suggests that complex formation between PAPP-A and STC2 is highly regulated, influencing height by up to 2.1 cm.
Researchers tracked COVID-19 symptoms in 158 untreated participants for 29 days and found that more than one-third experienced a return of symptoms after at least two consecutive days of being symptom-free. The most common relapsing symptoms were cough, fatigue, and headache.
Researchers at Kyoto University have developed a prodrug form of curcumin called TBP1901, which has shown anti-tumor effects without causing harm. The study found that TBP1901's conversion to active curcumin is dependent on the enzyme GUSB, suggesting its potential therapeutic targets.
A phase I clinical trial found that Omomyc (OMO-103) has few side effects and can stabilize disease in some patients. The treatment showed stabilization of disease in 8 out of 17 evaluable patients, including one patient with pancreatic cancer who remained on the study for over six months.
Researchers at UC San Diego identified a new signaling process involving GPCRs, suggesting untapped potential for therapies, including for multiple forms of cancer. The study challenges traditional views on GPCR-mediated signaling, revealing a new mechanism that originates at endosomes and propagates into the nucleus.
Researchers at VCU Massey Cancer Center have identified a new therapeutic target for triple-negative breast cancer (TNBC), a more aggressive and deadly form of disease. Using CRISPR/CAS9 screening, scientists pinpointed the UBA1 enzyme as an ideal target, which can be inhibited by the novel drug TAK-243 to effectively kill cancer cells.
Researchers have found a drug that targets the key, cancer-causing gene MYC has been able to inhibit its function safely and effectively. Eight out of 12 patients showed stabilisation of disease after treatment with OMO-103, with one patient experiencing a reduction in tumour-derived DNA circulating in the blood stream.
Researchers developed a new method to study membrane proteins in their native environment, the cell, using electron spin resonance spectroscopy. This technique allows for precise determination of protein properties and could lead to better understanding and targeting of membrane proteins involved in anti-cancer drug resistance.
A novel oxytocin derivative, PAS-CPPs-oxytocin, has been shown to improve cognitive function in mice with Alzheimer's-like symptoms. The derivative is delivered via intranasal administration and shows increased brain penetration compared to traditional intracerebroventricular delivery.
Researchers from Yokohama National University successfully generated hair follicles in cultures using organoid cultures. The study demonstrates the potential of hair follicle organoids for understanding hair follicle development and regeneration, as well as evaluating drugs for treating hair loss disorders.
Researchers have developed a novel method for antibiotic resistance testing that can analyze bacterial cells in real-time, allowing for faster identification of susceptible and resistant bacteria. This breakthrough technology has the potential to transform microbial screening in clinical and research labs.
Researchers have successfully blocked the adhesion mechanism of Bartonella henselae bacteria, preventing cell infection. The discovery offers a promising new approach to combat highly resistant infectious agents like Acinetobacter baumannii.
Scientists are conducting a first-of-its-kind study to investigate the origin of psychedelic compounds in fungi, including psilocybin found in 'magic mushrooms'. The research aims to understand the evolution of these compounds and their potential applications in medicine and conservation.
The study reveals how the activating partner PI5P interacts with two different regions of regulatory protein UHRF1, showing its role in modulating complex proteins. This finding could breathe new life into the search for UHRF1-directed medicines.
Coskun's team has developed SpatialVizScore, a new method that visualizes tumor immunology in cancer tissues to identify patients more likely to respond to immunotherapy. The system looks at the interactions of multiple immune cells, including macrophages with subtypes M1 and M2.
The Critical Path Institute has launched a pre-consortium collaboration with the FDA's CBER and CDER to accelerate medical product development in alpha-1 antitrypsin deficiency. The collaboration aims to define unmet needs in drug development and lay the groundwork for specific solutions.
A new study from Flinders University has shown that reboxetine, previously used to treat depression, can reduce obstructive sleep apnoea (OSA) severity. The study found that reboxetine alone reduces the number of sleep apnoea events per hour and improves oxygen levels.
Researchers at the University of Arizona have identified a protein called Ait1 that regulates cell growth in yeasts. This discovery presents new targets for developing antifungal drugs that can attack disease-causing yeasts while sparing human immune cells.
A new drug capsule developed at MIT may be able to replace injections for biologic drugs by tunneling through the mucus barrier in the small intestine. The capsule's robotic cap spins and displaces mucus, allowing drugs to pass into cells lining the intestine.
Researchers from Xi'an Jiaotong-Liverpool University found that brain stimulation combined with a nose spray containing nanoparticles can improve recovery after ischemic stroke. The treatment increased cognitive and motor functions, and weighed more quickly than those treated with TMS alone.
Researchers found no link between R&D costs and high drug prices in the US, contradicting industry claims. Despite $83 billion spent on R&D in 2019, drug prices are driven by market demand rather than investment costs.
A cross-sectional study of 60 new therapeutic agents found no association between research and development investments and treatment costs. The study's findings suggest that drug companies should make further data available to justify high prices.
A $1 million NIH grant will help MU researchers analyze the effectiveness of a HIPAA-secure text messaging platform in nursing homes. The study aims to improve quality of care and prevent costly hospital transfers by speeding up decision-making.
Monon Bioventures has received a grant to develop a novel glioblastoma treatment using armed natural killer cells. The treatment, created by Purdue University researcher Sandro Matosevic, shows promise in preclinical proof of concept and aims to manufacture the therapeutic for clinical studies.
Researchers at UMC Utrecht will investigate how intestinal microbiota impacts cancer immunotherapy and therapy side effects. The project aims to develop microbiota-targeted therapies to improve ICI treatment effectiveness and reduce severe inflammation.
Researchers discovered that autophagy facilitates the elimination of cancer cells via cell competition, highlighting its potential as a target for cancer prevention and treatment. The study sheds light on the role of autophagy in maintaining tissue homeostasis and opening avenues for novel anti-cancer therapeutics.
The Critical Path Institute (C-Path) has established a public-private partnership with the FDA and NIH to advance treatments for rare neurodegenerative diseases. The partnership will leverage C-Path's expertise in data management, quantitative analytics, and regulatory science to accelerate medical product development.
In a Phase I/II trial, selpercatinib demonstrated a 44% objective response rate across multiple tumor types, including pancreatic and colorectal cancers. The study found responses regardless of cancer type or prior treatment history, confirming RET fusions as a tissue-agnostic target.
Scientists at SLAC National Accelerator Laboratory have seen the critical interaction between SARS-CoV-2 protein Mpro and human immune system protein NEMO. The study reveals that Mpro can cut NEMO, slowing down the immune response and allowing the virus to evade the body.
A newly identified link between chronic pain and lung cancer in mice suggests that old drugs such as clonidine, capsaicin, and fluphenazine may offer new treatments for chronic pain. The study found that blocking the BH4 pathway reduced pain sensitivity and decreased tumor growth in mouse models of KRAS-driven lung cancer.
A new study suggests that the nuclear receptor TLX can inhibit the growth and progression of triple-negative breast cancer. TLX+ cells showed lower tumor growth, migration, and invasion rates compared to those without TLX expression.
Recent studies in Journal of Pharmaceutical Analysis highlight innovative nanosensors for efficient biomolecular detection, including rutin, paracetamol, and hypochlorite. These advancements enable high sensitivity and reliability in clinical samples, paving the way for improved patient care.
Researchers have identified dry voids in G protein-coupled receptors that are crucial for their activation and transmit signals to the cell interior. These unique binding sites differ among subclasses and offer a promising route for developing targeted therapies with fewer side effects.
Rice University researchers have developed a treatment combining drug factory implants producing interleukin-2 with checkpoint inhibitors to eradicate advanced-stage mesothelioma tumors in mice. The treatment resulted in complete tumor destruction in all seven treated mice, offering a promising approach to this aggressive lung cancer.
Researchers at Terasaki Institute create micro-organospheres for direct viral infection, immune cell penetration, and high-throughput therapeutic drug screening. The technology holds promise for personalized medicine, tumor therapy and rapid drug testing.
A new gene variant, MFGE8, has been discovered that protects against coronary heart disease, with carriers experiencing a one-fifth lower risk. The variant is located in the MFGE8 gene and inhibits the function of lactadherin protein, which affects arterial stiffness.
A recent study published in Cancer Research identified a unique vulnerability in certain high-risk cancers that can be exploited for targeted therapy. Researchers found that cancer cells with alternative lengthening of telomeres (ALT) have a common weakness, leading to resistance to DNA-damaging agents and chemotherapy.
Researchers at NTNU have developed a digital system called Drugvirus.info that can identify the most effective medicinal mix against viruses, reducing development time from years to months. This approach could lead to the creation of new treatments for 200 viral diseases, saving millions of euros and lives.
Researchers at Weill Cornell Medicine found that disrupting circadian clocks leads to increased fat cell growth and insulin production. Stress and other factors can throw the body's 'clocks' out of rhythm, contributing to weight gain.
Researchers identified CUDC907 as a dual phosphoinositide-3 kinase/histone deacetylase inhibitor that promotes apoptosis in NF2 schwannoma cells. The compound reduced viability and induced cell cycle arrest in human merlin deficient Schwann cell models.
Researchers developed a mathematical model to predict the efficiency of nanoparticle delivery into cells, particularly in stem cells. They found that nanoparticles become trapped in bubble-like vesicles, preventing them from reaching their targets.
MU researchers have identified specific mutations in the Omicron variant's spike protein that help it evade existing antibodies from vaccines or previous COVID-19 infections. These findings can inform developers of COVID-19 treatments and vaccines, which may need to target different parts of the virus to produce effective outcomes.
A new report highlights the importance of acknowledging antimicrobial resistance (AMR) in regulatory frameworks for accelerated drug approval. The analysis provides recommendations to improve access to new antibiotics in Brazil, India, and South Africa, where antibiotic development is hampered by regulatory hurdles.
The WHO advises against the use of colchicine and fluvoxamine for treating non-severe COVID-19, citing insufficient evidence and potential harms. No recommendation is made for these drugs in patients with severe or critical illness.
Researchers at Aarhus University have developed an easy and inexpensive method for linking molecules to DNA sequences with desired functions. The method uses sulfonyl azides to introduce various functionalities, avoiding the need for expensive and unstable special phosphoramidites.
Researchers from PSI, EPFL, and the University of Geneva developed a new method to distinguish between mirror-image molecules using helical dichroism. This approach provides stronger signals compared to circular dichroism (CD), which is widely used but has weak signals suitable only for gas-phase samples.